Checkpoint Therapeutics CEO James F. Oliviero III Sells Shares

On February 7th, James F. Oliviero III, the CEO of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT), sold 9,233 shares of the company’s stock. The shares were sold at an average price of $3.41, amounting to a total transaction value of $31,484.53. After this sale, Oliviero now directly owns 3,785,350 shares of Checkpoint Therapeutics, which are valued at approximately $12,908,043.50. This transaction represents a decrease of 0.24% in his stake in the company. The details of this sale have been reported in a filing with the Securities and Exchange Commission (SEC), which can be accessed via a hyperlink.

Performance of Checkpoint Therapeutics Stock

On Wednesday, Checkpoint Therapeutics stock opened at $3.13. The company has a market capitalization of $152.84 million, a negative P/E ratio of -1.70, and a beta of 1.36. The 50-day moving average price stands at $3.39, while the 200-day moving average price is $2.99. Over the past year, the stock hit a low of $1.38 and peaked at $4.50.

Recently, Checkpoint Therapeutics announced its earnings on November 12th. The company reported earnings per share (EPS) of ($0.23) for the quarter, which was lower than the consensus estimate of ($0.15) by $0.08. Analysts project that Checkpoint Therapeutics will report an EPS of -0.94 for the current year.

Institutional Investment Activity in Checkpoint Therapeutics

Multiple institutional investors have been active in buying and selling shares of Checkpoint Therapeutics. For example, during the third quarter, Virtu Financial LLC acquired a new position in the company, which is valued at approximately $30,000. In the fourth quarter, SBI Securities Co. Ltd. purchased a new stake worth around $32,000, while PUREfi Wealth LLC also acquired shares valued at $32,000. Furthermore, Bartlett & CO. Wealth Management LLC significantly increased their holdings in the fourth quarter by 375%, bringing their total ownership to 19,000 shares, worth $61,000. Charles Schwab Investment Management Inc. similarly invested in the company during the fourth quarter, with a new position valued at $64,000. Currently, approximately 22.00% of Checkpoint Therapeutics' stock is owned by institutional investors and hedge funds.

Analysts' Ratings and Commentary on CKPT Shares

Several analysts have recently shared their views on Checkpoint Therapeutics. HC Wainwright reaffirmed a "buy" rating with a target price of $20.00 in a research report issued on December 16th. D. Boral Capital initiated coverage on the company on January 13th and assigned a "buy" rating, with a price target set at $9.00. Lake Street Capital also increased their target price for Checkpoint Therapeutics from $4.00 to $7.00 and reiterated a "buy" rating in their report released on December 16th.

Company Overview of Checkpoint Therapeutics

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc. is a clinical-stage company focused on immunotherapy and targeted oncology. The firm is devoted to acquiring, developing, and commercializing novel treatments for patients with solid tumor cancers, both in the U.S. and internationally. Their leading product candidate is Cosibelimab, which is currently undergoing Phase 1 clinical trials aimed at treating selected recurrent or metastatic cancers. Additionally, they have CK-302, which is in preclinical trials targeting hematological malignancies and solid tumors.

CEO, stock, sale